Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why Natera (NTRA) Shares Are Falling Today

September 10, 2025 at 15:11 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

NTRA Cover Image

What Happened?

Shares of genetic testing company Natera (NASDAQ: NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood test.

Exact Sciences, a leader in cancer diagnostics, launched its Cancerguard™ test, which is now available as a laboratory-developed test in the United States. This move introduces significant competition in the early cancer detection market, a key area for Natera, likely raising investor concerns about market share and future growth.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Natera? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Natera’s shares are quite volatile and have had 17 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 12 days ago when the stock dropped 0.9% on the news that the company announced an unfavorable court ruling in its ongoing patent litigation with competitor NeoGenomics.

The U.S. District Court for the Middle District of North Carolina invalidated certain claims in two patents that Natera had asserted against NeoGenomics' v1.1 RaDaR test. This legal setback was seen as a victory for NeoGenomics, whose own stock surged on the news. Natera stated that it is evaluating its options, which include a potential appeal. The company also clarified that the ruling does not impact a separate patent that was previously used to secure an injunction against an earlier version of the NeoGenomics product. Nevertheless, the invalidation of these patent claims represents a significant headwind in Natera's efforts to protect its intellectual property.

Natera is up 4.6% since the beginning of the year, and at $167.92 per share, it is trading close to its 52-week high of $177 from February 2025. Investors who bought $1,000 worth of Natera’s shares 5 years ago would now be looking at an investment worth $2,720.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article